Announcements Trials
Browse Landscape

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Plasma cell 1Other 1

Conditions

Neoplasms 10Lung Neoplasms 9Colorectal Neoplasms 7Breast Neoplasms 7Prostatic Neoplasms 6Rectal Neoplasms 3Polycystic Ovary Syndrome 3Neoplasm Metastasis 3Colonic Neoplasms 3Stomach Neoplasms 2Smoking Cessation 2Neoplastic Cells, Circulating 2Motor Activity 2Lymphoma 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia 2Endometrial Neoplasms 2Disease 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Venous Thromboembolism 1Vaginal Neoplasms 1Uveal Melanoma 1Uterine Cervical Neoplasms 1Untreated Human Epidermal Growth Factor Receptor-2(HER2)Positive Early Breast Cancer 1Testicular Germ Cell Tumor 1Stroke 1Solitary Pulmonary Nodule 1Skin Neoplasms 1Sezary Syndrome 1

Interventions

Dexamethasone 420Lenalidomide 265Cyclophosphamide 246Bortezomib 242Melphalan 192Calcium Dobesilate 166fludarabine phosphate 112daratumumab 103Peripheral Blood Stem Cell Transplantation 99carfilzomib 92Thalidomide 90Filgrastim 88Mycophenolic Acid 82fludarabine 81pomalidomide 80Whole-Body Irradiation 80Busulfan 74Tacrolimus 71Granulocyte Colony-Stimulating Factor 66Cyclosporine 58dexamethasone acetate 56ixazomib 55Antilymphocyte Serum 50dexamethasone 21-phosphate 49auricularum 44isatuximab 40Etoposide 39Radiotherapy 36Stem Cell Transplantation 34Methotrexate 33

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Multiple Myeloma × Hematologic Tests × Clear all
NCT04827563 2026-03-04

Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive Carfilzomib

University of Chicago

Terminated
50 enrolled
OtherPlasma cell

Dyspnea, Multiple Myeloma, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡